ClinicalTrials.gg
RecruitingNCT06831136PANCARDINAL-2Updated Oct 8, 2026

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

A Phase 2 interventional study of Neoadjuvant Chemotherapy (NAC) and Immunotherapy (pembrolizumab) in Pancreatic Ductal Adenocarcinoma, sponsored by The University of Texas Health Science Center, Houston. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by The University of Texas Health Science Center, Houston · Phase 2, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Oct 8, 2026Eligibility revisedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,057 studies in Neoplasm Metastasis with a site in United States — 344 open to participants now, 544 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
1,282nd of 1,866
24 · median 43
Started
2025
with 84 others
Phase 2
565 of 2,057
58 open now
Primary completion
2028-01
later than 349 of 542 live
Registered
1,911th of 2,057
by date

Among the 2,057 studies in Neoplasm Metastasis with a site in United States, this one is the 1,282nd largest by planned enrollment of the 1,866 interventional ones that give a count, is one of 85 that started in 2025, is one of 565 in phase 2, reaches primary completion later than 349 of the 542 other live ones, and was the 1,911th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

344 of the 2,057 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

339 more — sign in →

All 344 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,057 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to perform a pilot phase II trial to evaluate the safety and efficacy of combined EUS-RFA, chemotherapy, and systemic immunotherapy (pembrolizumab) for the treatment of locally advanced unresectable and metastatic Pancreatic ductal adenocarcinoma (mPDAC).

03

Conditions studied

  • Pancreatic Ductal Adenocarcinoma

Keywords

  • metastatic cancer
  • chemotherapy
  • systemic immunotherapy
  • pembrolizumab
  • neoplasms
  • Endoscopic Ultrasound Radiofrequency ablation (EUS-RFA)
04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is willing and able to comply with the protocol for the duration of the study,including undergoing treatment and scheduled visits and examinations, including follow-up
  • -proven locally advanced unresectable or PDAC

    1. Patients who have undergone prior resection will be excluded unless there is recurrent pancreatic tumor that is amenable to EUS-RFA.
    2. If biliary metal stent is placed, during procedure of EUS-RFA, indwelling biliary metal stent will be removed during initial EUS-RFA and then replaced with plastic stent.
  • Mental capacity to provide , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
  • (ECOG) Performance status 0-2
  • At least one measurable metastatic lesion on axial imaging per (RECIST) v1.
  • No prior systemic therapy, including chemotherapy or chemoradiation is permitted with the following exceptions:

    1. Prior therapy (including chemotherapy and/or radiotherapy) for pancreatic adenocarcinoma is permitted if standard of care neoadjuvant or adjuvant therapy was completed at least 3 months prior to study enrollment. Prior adjuvant therapy may include mFFX, NALIRIFOX, GA or Capecitabine (Xeloda).
    2. If started on treatment for mPDAC elsewhere (i.e., not at our study site), eligible participants can have undergone 3 months of chemotherapy with clinically stable disease (defined as no evidence of clinical progression) before study entry. Note: Imaging done outside the site will need to be reviewed for a 2nd opinion to confirm stable disease.

    i. For patients who had prior treatment and stable disease up to 3 months and confirmed radiographically by our radiology investigators, then patients can proceed with EUS-RFA within 6-8 weeks of enrollment of study.

    c. Patients who have started chemotherapy within a 3-month timeframe are allowed.

  • (ANC) ≥1 x 109/L
  • count ≥75 x 109/L
  • Albumin levels ≥3 g/dL
  • Total serum \<2× (ULN) unless secondary to Gilbert's Syndrome

    a. Subjects requiring biliary decompression, biliary stent, or drainage using percutaneous trans-hepatic cholangiogram are allowed (patients with a declining bilirubin status post stent placement are eligible with serum bilirubin ≤2.5 x ULN)

  • (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤3× ULN, or ≤5× ULN in cases of documented liver involvement
  • Serum must be ≥30 mL/minute either measured or calculated using a standard Cockcroft and Gault formula
  • Prior surgery that required general anesthesia or other major surgery as defined by the Investigator must be completed at least 4 weeks before immunotherapy.

Exclusion criteria

Exclusion Criteria:

  • No telephone number and permanent street address
  • Pregnant or breastfeeding patients; or is a male or female patient of who is not willing to employ effective from time of screening to 90 days after the last dose
  • Inmates or prisoners
  • Unable to provide
  • Resectable, borderline resectable PDAC.
  • Known history of central nervous system (CNS)
  • Has a history of another primary . Patients having the following are still eligible:

    1. No active stage 4 cancer
    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    3. Adequately treated carcinoma in situ without evidence of disease
  • Known low or absent dihydropyrimidine dehydrogenase (DPD) activity
  • Use of strong inhibitors or inducers of Cytochrome P450 3A (), CYP2C8 and UGT1A1
  • History or evidence of or uncontrolled cardiovascular, CNS,and/or other systemic disease that in the investigator's opinion would preclude participation in the study or compromise the patient's ability to give informed consent
  • History of or active tuberculosis (TB) (PPD response without active TB is allowed)
  • Underlying medical conditions that, in the Investigator's opinion, will make the administration of pembrolizumab hazardous (e.g., interstitial lung disease, active infections requiring antibiotics, recent hospitalization with unresolved symptoms)
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • Any active disease or a documented history of autoimmune disease or history of a syndrome that required systemic or medications, except for vitiligo or resolved childhood asthma/atopy and the following scenarios below:

    1. Participants with asthma who require intermittent use of bronchodilators (such as albuterol) will not be excluded from this study.
    2. Physiologic doses of corticosteroids (≤10 mg/day of prednisone or its equivalent) or short pulses of corticosteroids (≤3 days) may be permitted.
    3. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
    4. Patients having any chronic skin condition that does not require systemic therapy
    5. Patients without active disease in the last 5 years (allowed only after consultation with the study physician)
    6. Patients with celiac disease controlled by diet alone
  • Is currently using or previously used immunosuppressive medication within 14 days before the first dose of pembrolizumab. The following medications are exceptions to this criterion:

    1. intranasal, inhaled, topical steroid, or local steroid injections (e.g., intra articular injection)
    2. Systemic corticosteroids at physiologic doses not to exceed 10mg/day of prednisone or its equivalent
    3. steroids as premedication for reactions (e.g., computer tomography [CT] scan premedication)
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Standard of care chemotherapy + immunotherapy + EUS-RFA

    Drug: Neoadjuvant Chemotherapy (NAC) · Drug: Immunotherapy (pembrolizumab) · Device: Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA)

Interventions

  • DrugNeoadjuvant Chemotherapy (NAC)

    Participant will undergo 8 weeks of NAC (treating physician's choice). Possible regimens are either mFOLFIRINOX or NALIRIFOX or Gemcitabine Nab-Paclitaxel ± Cisplatin (GA+/-Cisplatin) or Capecitabine (Xeloda).

  • DrugImmunotherapy (pembrolizumab)

    2-12 weeks after initial chemotherapy and after the first EUS-RFA treatment, patients will receive 400 mg every 6 weeks of pembrolizumab via infusion. Participants will be administered standard of care chemotherapy and pembrolizumab every 6 weeks.

  • DeviceEndoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA)

    After 2-12 weeks of chemotherapy, patients will undergo EUS-RFA treatment 1 session every 6 weeks. Each RFA treatment will be for up to 5 cycles at 30W for 20 seconds or until there is an increase in measured impedance. After the 5th EUS-RFA, if there is clinical benefit, then patients will continue with EUS-RFA treatments until no active tumor is seen. During each session, the therapeutic gastroenterologist will evaluate if there is any tumor to undergo RFA. If no active tumor seen, then will abort RFA

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Efficacy as assessed by the Overall response rate using RECIST v1.1 guidelines

    (ORR) is defined as proportion of patients with complete response (CR) or partial response (PR)

    Time frame: From date of diagnosis to the initial date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months.

Secondary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: From the date of the initiation of study treatment until 30 days after the last dose of study treatment, withdrawal of consent, or study termination

  2. Incidence of serious adverse events (SAEs)

    Time frame: From the date of the initiation of study treatment until 30 days after the last dose of study treatment, withdrawal of consent, or study termination

  3. Duration of response (DOR)

    DOR is defined as elapsed time between date of documented response (CR or PR) and date of progression or date of death from any cause.

    Time frame: Every 8 weeks from the time of enrollment to the date of death due to any causes for up to 5 years

  4. Progression-free survival (PFS)

    Progression-free survival (PFS) is defined as elapsed time between start date of treatment and date of progression or date of death from any cause.

    Time frame: Every 8 weeks from the time of enrollment to the date of death due to any causes for up to 5 years

  5. Overall survival (OS)

    Overall survival (OS) is defined as elapsed time between start date of treatment and date of death from any cause.

    Time frame: Every 8 weeks from the time of enrollment to the date of death due to any causes for up to 5 years

  6. Local (distant) recurrence rate

    Local (distant) recurrence rate is defined as incidence rate of local (distant) recurrence

    Time frame: Every 8 weeks from the time of enrollment to the date of death due to any causes for up to 5 years

  7. Local (distant) recurrence time

    Local (distant) recurrence time is defined as the elapsed time between start date of treatment and date of the first local (distant) recurrence.

    Time frame: Every 8 weeks from the time of enrollment to the date of death due to any causes for up to 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jan 2028, 33 months after the start.

Of 354 non-industry phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 90. This study's planned 33 months is below that.

Counting every sponsor, half of 442 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2025
First posted
Feb 17, 2025
StartActual
Mar 26, 2025
Primary completionEst.
Jan 20, 2028
CompletionEst.
Jan 20, 2030
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedIf started on first-line treatment for mPDAC elsewhere (i.e., not at our study site), eligible participants can have undergone 3 months of chemotherapy with clinically stable disease (defined as no evidence of clinical progression) before study entry. Note: Imaging done outside the site will need to be reviewed for a 2nd opinion to confirm stable disease.
Oct 8, 2026
Contact
Study contact changed: p•••@uth.tmc.edu · •••7705→E•••@uth.tmc.edu · •••4895; A•••@uth.tmc.edu · •••5377→U•••@uth.tmc.edu · •••6919. See the current contact
Oct 8, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • The University of Texas Health Science Center at Houston · Houston, United StatesContact p•••@uth.tmc.edu · •••7705→E•••@uth.tmc.edu · •••4895Contact A•••@uth.tmc.edu · •••5377→U•••@uth.tmc.edu · •••6919
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedIf started on first-line treatment for mPDAC elsewhere (i.e., not at our study site), eligible participants can have undergone 3 months of chemotherapy with clinically stable disease (defined as no evidence of clinical progression) before study entry. Note: Imaging done outside the site will need to be reviewed for a 2nd opinion to confirm stable disease.
    Contact Study contact changed: p•••@uth.tmc.edu · •••7705→E•••@uth.tmc.edu · •••4895; A•••@uth.tmc.edu · •••5377→U•••@uth.tmc.edu · •••6919. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • The University of Texas Health Science Center at Houston · Houston, United StatesContact p•••@uth.tmc.edu · •••7705→E•••@uth.tmc.edu · •••4895Contact A•••@uth.tmc.edu · •••5377→U•••@uth.tmc.edu · •••6919
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06831136
Responsible party
Putao Cen (Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Feb 17, 2025
Start date
Mar 26, 2025
Primary completion
Jan 20, 2028 (estimated)
Completion
Jan 20, 2030 (estimated)
Last update
Oct 8, 2026

Study contacts

Elnaz Ghalechi
Contact
Elnaz.RezaeiGhalechi@uth.tmc.edu
713-500-4895
Umer Soomro
Contact
Umer.T.Soomro@uth.tmc.edu
(713) 500-6919
Putao Cen
principal investigator · The University of Texas Health Science Center, Houston

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion